![Vijay Samant](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vijay Samant
Directeur/Bestuurslid bij
Xiconic Pharmaceuticals LLC
Profiel
Vijay B. Samant currently works at Xiconic Pharmaceuticals LLC, as Director.
Mr. Samant also formerly worked at Vical, Inc., as President, Chief Executive Officer & Director from 2000 to 2019, AmpliPhi Biosciences Corp., as Independent Director from 2015 to 2019, Materials Management, Inc., as Executive Director, BioMarin Pharmaceutical, Inc., as Director from 2002 to 2004, Aeras Global TB Vaccine Foundation, as Director in 2010, Raptor Pharmaceuticals Corp., as Director from 2011 to 2014, Horizon Pharmaceutical LLC, as Independent Director from 2011 to 2014, Fresh Tracks Therapeutics, Inc., as Independent Director from 2000 to 2023, Merck & Co., Inc., as Chief Operating Officer-Vaccine Division from 1998 to 2000, National Foundation for Infectious Diseases, as Trustee from 2003 to 2012, and International Vaccine Institute, as Trustee from 2011 to 2012.
Mr. Samant received his graduate degree in 1977 from The Trustees of Columbia University in The City of New York, undergraduate degree in 1975 from the University of Mumbai, and Masters Business Admin degree in 1983 from MIT Sloan School of Management.
Actieve functies van Vijay Samant
| Bedrijven | Functie | Begin |
|---|---|---|
Xiconic Pharmaceuticals LLC
 Xiconic Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Founded in 2016, Xiconic Pharmaceuticals LLC is a biopharmaceutical company focused on developing cancer treatments. The company is based in Blue Bell, PA. The company advances a novel tumor antigen discovery—activated matriptase (actm)—which is predominantly expressed on tumor cells across multiple epithelial cancers and certain lymphomas. Xiconic's lead product, XCN-010 (matriptimab™-mmae), is a first-in-class antibody-drug conjugate that selectively targets actm using the M69 monoclonal antibody. XCN-010 employs proprietary pegylation technology to enhance linker stability, reduce off-target toxicity, and enable efficient intracellular release of the potent microtubule inhibitor monomethyl auristatin e (mmae), with a drug-antibody ratio accepted by the FDA. Preclinical studies demonstrate XCN-010’s potency and selectivity against actm-positive tumor cells in vitro and efficacy in multiple in vivo tumor models, including breast, non-small cell lung, prostate cancers, and mantle cell lymphoma. Combination therapy with olaparib further enhances antitumor effects without added toxicity. The company has licensed key intellectual property from Rutgers and Georgetown universities and is progressing toward clinical development. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Vijay Samant
| Bedrijven | Functie | Einde |
|---|---|---|
| FRESH TRACKS THERAPEUTICS, INC. | Directeur/Bestuurslid | 02-10-2023 |
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Algemeen Directeur | 01-08-2019 |
AmpliPhi Biosciences Corp.
 AmpliPhi Biosciences Corp. BiotechnologyHealth Technology Develops and commercializes novel bacteriophage-based therapeutics | Directeur/Bestuurslid | 01-01-2019 |
| RAPTOR PHARMACEUTICAL CORP | Directeur/Bestuurslid | 28-07-2014 |
Raptor Pharmaceuticals Corp.
 Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Develops drugs and drug-delivery platforms | Directeur/Bestuurslid | 01-01-2014 |
Opleiding van Vijay Samant
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
88
Eerstegraads connecties
15
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 15 |
|---|---|
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Health Technology |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology Develops and commercializes novel bacteriophage-based therapeutics | Health Technology |
Materials Management, Inc.
 Materials Management, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in planning and management of precious metal assets | Commercial Services |
BioMarin Pharmaceutical, Inc.
 BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions | Health Technology |
Aeras Global TB Vaccine Foundation
 Aeras Global TB Vaccine Foundation Miscellaneous Commercial ServicesCommercial Services Aeras Global TB Vaccine Foundation is a non-profit organization, which engages in the development of tuberculosis vaccines in partnership with other biotech, pharmaceutical, and academic organizations. Its product pipeline includes AdS Ag85A, MTBCAV, VPM 1002, and RUTI. The company is headquartered in Rockville, MD. | Commercial Services |
The Trustees of Columbia University in The City of New York
 The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Mumbai
 University of Mumbai Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Develops drugs and drug-delivery platforms | Health Technology |
National Foundation for Infectious Diseases
 National Foundation for Infectious Diseases Miscellaneous Commercial ServicesCommercial Services Operates voluntary health organization | Commercial Services |
International Vaccine Institute
 International Vaccine Institute Miscellaneous Commercial ServicesCommercial Services Develops and distributes vaccines | Commercial Services |
Horizon Pharmaceutical LLC
 Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of life-altering therapeutics that treat debilitating and often fatal diseases | Health Technology |
MIT Sloan School of Management
 MIT Sloan School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fresh Tracks Therapeutics, Inc.
 Fresh Tracks Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates pharmaceutical company that develops and manufactures prescription therapeutics products for the treatment of autoimmune, inflammatory and debilitating diseases | Health Technology |
Xiconic Pharmaceuticals LLC
Xiconic Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Founded in 2016, Xiconic Pharmaceuticals LLC is a biopharmaceutical company focused on developing cancer treatments. The company is based in Blue Bell, PA. The company advances a novel tumor antigen discovery—activated matriptase (actm)—which is predominantly expressed on tumor cells across multiple epithelial cancers and certain lymphomas. Xiconic's lead product, XCN-010 (matriptimab™-mmae), is a first-in-class antibody-drug conjugate that selectively targets actm using the M69 monoclonal antibody. XCN-010 employs proprietary pegylation technology to enhance linker stability, reduce off-target toxicity, and enable efficient intracellular release of the potent microtubule inhibitor monomethyl auristatin e (mmae), with a drug-antibody ratio accepted by the FDA. Preclinical studies demonstrate XCN-010’s potency and selectivity against actm-positive tumor cells in vitro and efficacy in multiple in vivo tumor models, including breast, non-small cell lung, prostate cancers, and mantle cell lymphoma. Combination therapy with olaparib further enhances antitumor effects without added toxicity. The company has licensed key intellectual property from Rutgers and Georgetown universities and is progressing toward clinical development. | Health Technology |
